3970-39-6

Basic information

• Product Name: Benzene, 2-chloro-1-methoxy-3-nitro-
• Synonyms: Benzene, 2-chloro-1-methoxy-3-nitro-;2-Chloro-3-nitroanisole;2-Chloro-3-methoxy-1-nitrobenzene;2-Chloro-1-methoxy-3-nitrobenzene;2-chloro-1-Methoxy-3-nitro-
• CAS NO: 3970-39-6
• Molecular Formula: C₇H₆ClNO₃
• Molecular Weight: 187.58
• Product Categories: API intermediates;Anisoles, Alkyloxy Compounds & Phenylacetates;Chlorine Compounds;Nitro Compounds
• Mol File: 3970-39-6.mol
• Article Data: 11

Chemical Properties

• Melting Point: 93-94 °C
• Boiling Point: 290.313 °C at 760 mmHg
• Flash Point: 129.377 °C
• Appearance: /
• Density: 1.367 g/cm³
• Vapor Pressure: 0.004mmHg at 25°C
• Refractive Index: 1.56
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: Benzene, 2-chloro-1-methoxy-3-nitro-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzene, 2-chloro-1-methoxy-3-nitro-(3970-39-6)
• EPA Substance Registry System: Benzene, 2-chloro-1-methoxy-3-nitro-(3970-39-6)

Safety Data

• Hazardous Substances Data: 3970-39-6(Hazardous Substances Data)

Usage

General Description

2-Chloro-1-methoxy-3-nitrobenzene, also known as 2-chloro-1-methoxy-3-nitrobenzene, is an organic compound with the chemical formula C7H6ClNO3. It is a pale yellow solid that is used as a synthetic intermediate in the production of various pharmaceuticals and agrochemicals. Benzene, 2-chloro-1-methoxy-3-nitro- is considered to be toxic if inhaled or ingested and can cause irritation to the skin and eyes. It is also classified as a hazardous substance and must be handled with care. Its use and production are regulated due to its potential environmental and health hazards.

InChI:InChI=1/C7H6ClNO3/c1-12-6-4-2-3-5(7(6)8)9(10)11/h2-4H,1H3

Upstream product

• 603-84-9 2-chloro-3-nitrophenol 
• 77-78-1 dimethyl sulfate 
• 74-88-4 methyl iodide 
• 603-85-0 2-Amino-3-nitrophenol 
• 562-54-9 potassium methyl sulfate 
• 16554-45-3 2-methoxy-6-nitroaniline 
• 62153-30-4 acetic acid-(4-methoxy-2,3-dinitro-anilide) 
• 5473-00-7 4-methoxy-2,3-dinitro-aniline 
• 16315-07-4 2,3-dinitroanisole 

Downstream Products

• 65516-73-6 2,3-dimethylthioanisole 
• 146012-36-4 2,2'-dichloro-3,3'-dimethoxyhydrazobenzene 
• 30748-92-6 2-(2-methoxy-6-nitrophenylamino)propionic acid ethyl ester 
• 1427029-27-3 1-(2,6-dichlorophenyl)-6-methoxy-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline 
• 174913-11-2 3-bromo-2-chloro-anisole 
• 860466-30-4 (2-methoxy-ethyl)-(2-methoxy-6-nitro-phenyl)-amine 
• 65516-92-9 2,3-Bis(methylsulfonyl)anisol 
• 2942-19-0 7-methoxy-2-(methylthio)benzo[d]thiazole 
• 106422-29-1 3-Methoxy-2-(3-methoxy-phenoxy)-phenol 
• 106272-26-8 3-methoxy-2-(3-methoxy-phenoxy)-aniline 

Relevant articles and documents

Induction of Axial Chirality in 8-Arylquinolines through Halogenation Reactions Using Bifunctional Organocatalysts

The enantioselective syntheses of axially chiral heterobiaryls were accomplished through the aromatic electrophilic halogenation of 3-(quinolin-8-yl)phenols with bifunctional organocatalysts that control the molecular conformations during successive halogenations. Axially chiral quinoline derivatives, which have rarely been synthesized in an enantioselective catalytic manner, were afforded in moderate-to-good enantioselectivities through bromination, and an analogous protocol also enabled enantioselective iodination. In addition, this catalytic reaction, which allows enantioselective control through the use of mono-ortho-substituted substrates, allowed the asymmetric synthesis of 8-arylquinoline derivatives bearing two different halogen groups in high enantioselectivities.

Penta-substituted benzimidazoles as potent antagonists of the calcium-sensing receptor (CaSR-antagonists)

A series of novel benzimidazole derivatives has been designed via a scaffold morphing approach based on known calcilytics chemotypes. Subsequent lead optimisation led to the discovery of penta-substituted benzimidazoles that exhibit attractive in vitro and in vivo calcium-sensing receptor (CaSR) inhibitory profiles. In addition, synthesis and structure-activity relationship data are provided.

HEPATITIS C INHIBITOR DIPEPTIDE ANALOGS

The present invention relates to compounds of formula (I): wherein R1, R2, R4, n and m are as defined herein and R3 is selected from: (i) -C(O)OR31 wherein R31 is (C1-6)alkyl or aryl, wherein the (C1-6)alkyl is optionally substituted with one to three halogen substituents; (ii) -C(O)NR32R33, wherein R32 and R33 are each independently selected form H, (C1-6)alkyl, and Het; (iii) -SOvR34, wherein v is 1 or 2 and R34 is selected from: (C1-6)alkyl, aryl, Het, and NR32R33 wherein R32 and R33 are as defined above; and (iv) -CO(O)-R35, wherein R35 is selected from (C1-8)alkyl, (C3-7)cycloalkyl-(C1-4)alkyl, aryl, aryl-(C1-6)alkyl, Het and Het-(C1-6)alkyl, each of which are optionally substituted with one or more substituents each independently selected from halo, (C1-6)alkyl, (C3-7)cycloalkyl, aryl, Het, hydroxyl, -O-(C1-6)alkyl, -S-(C1-6)alkyl, -SO-(C1-6)alkyl, -SO2-(C1-6)alkyl, -O-aryl, -S-aryl, -SO-aryl and -SO2-aryl, wherein the aryl portion of the -O-aryl, -S-aryl, -SO-aryl and -SO2-aryl are each optionally substituted with one to five halo substituents. The present invention further relates to pharmaceutical compositions containing the compounds of formula (I) and methods for using these analogs in the treatment of HCV infection.